Pyxis Oncology, Inc. (PYXS)
$3.23-$0.09 (-2.72%) Today
Thomas Civik - OfficerPyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 1 | 35,000 | $107K |
| Grant or award | 2 | 296,956 | |
| Option exercise | 2 | 70,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
17 Form 4 filings on record, the earliest from Nov 27, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jakob Dupont - Director | Grant or award | Stock Option (Right to Buy) | 46,000 | $0.00 | - | |
| Thomas Civik - Officer | Grant or award | Stock Option (Right to Buy) | 250,956 | $0.00 | - | |
| Jakob Dupont | Option exercise | Common Stock | 35,000 | $1.60 | $56K | |
| Jakob Dupont | Open-market sale | Common Stock | 35,000 | $3.06 | $107K | |
| Jakob Dupont | Option exercise | Stock Option (Right to Buy) | 35,000 | $0.00 | - | |
| Jakob Dupont | Grant or award | Stock Option (Right to Buy) | 45,867 | $0.00 | - | |
| Jitendra Wadhane - Officer | Grant or award | Common Stock | 109,461 | $0.00 | - | |
| Jitendra Wadhane - Officer | Grant or award | Stock Option (Right to Buy) | 262,635 | $0.00 | - | |
| John L. Flavin | Grant or award | Stock Option (Right to Buy) | 45,867 | $0.00 | - | |
| Michael A. Metzger | Grant or award | Stock Option (Right to Buy) | 45,867 | $0.00 | - | |
| Freda C. Lewis-Hall | Grant or award | Stock Option (Right to Buy) | 45,867 | $0.00 | - | |
| Darren S. Cline | Grant or award | Stock Option (Right to Buy) | 45,867 | $0.00 | - | |
| Rachel Humphrey | Grant or award | Stock Option (Right to Buy) | 45,867 | $0.00 | - | |
 Santhosh Palani | Grant or award | Stock Option (Right to Buy) | 45,867 | $0.00 | - | |
| Thomas Civik - Officer | Grant or award | Stock Option (Right to Buy) | 690,131 | $0.00 | - | |
| John L. Flavin | Grant or award | Stock Option (Right to Buy) | 36,979 | $0.98 | $36K | |
| Lara Sullivan - Officer | Grant or award | Stock Option (Right to Buy) | 1,135,000 | $0.00 | - | |
| Pamela Ann Connealy - Officer | Grant or award | Stock Option (Right to Buy) | 310,000 | $0.00 | - | |
| Jitendra Wadhane - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | $0.00 | - | |
| Pamela Ann Connealy - Officer | Open-market purchase | Common Stock | 5,450 | $2.00 | $11K | |
| Pamela Ann Connealy - Officer | Open-market purchase | Common Stock | 83,400 | $1.96 | $163K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
Pyxis Oncology, Inc. (PYXS) had 3 insider filings in the last 90 days, with the most recent on 2026-08-20. The full record for PYXS runs to 17 Form 4 filings, the earliest from 2024-11-27. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of PYXS were filed in the last 90 days. 2 purchases are on record for this company.
1 insider sale of PYXS was filed in the last 90 days, totaling $107K.
This page tracks PYXS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add PYXS to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
